Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice

Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in... Dear Editor,Erythrodermic psoriasis (EP) is a rare and severe clinical form of psoriasis. Due to its low incidence, treatment is not standardized. Secukinumab (SEC) is an anti‐interleukin‐17A monoclonal antibody approved for the treatment of plaque psoriasis.1 However, there are only few reports, including small case series, on its use for EP treatment in daily practice.2–5We designed a retrospective, observational, non‐controlled, multicentre cohort study of patients with EP treated with SEC in daily practice conditions conducted between December 2015 and July 2020. Dermatologists from one Portuguese and six Spanish hospitals participated in this study. Inclusion criteria were (1) adults diagnosed of EP (involvement of >80% of body surface area) treated with SEC in a daily practice setting; (2) initial standard dose regimen of SEK; (3) follow‐up for at least 3 months. Effectiveness (Psoriasis Area and Severity Index, PASI) and quality of life (Dermatology Life Quality Index, DLQI) were evaluated through both. As observed and last observation carried forward (LOCF) analyses.Sixteen patients were included in the study. Baseline characteristics of the patients are summarized in Table 1. Five (31.2%) and 7 (43.7%) patients were naïve to conventional and biologic systemic therapy, respectively. Mean PASI, absolute and relative PASI, DLQI and Physician Global assessment http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology and Venereology Wiley

Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice

Download PDF
3 pages

Loading next page...
 
/lp/wiley/effectiveness-of-secukinumab-for-the-treatment-of-erythrodermic-OWueRPrila

References (6)

Publisher
Wiley
Copyright
Copyright © 2023 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
DOI
10.1111/jdv.19371
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,Erythrodermic psoriasis (EP) is a rare and severe clinical form of psoriasis. Due to its low incidence, treatment is not standardized. Secukinumab (SEC) is an anti‐interleukin‐17A monoclonal antibody approved for the treatment of plaque psoriasis.1 However, there are only few reports, including small case series, on its use for EP treatment in daily practice.2–5We designed a retrospective, observational, non‐controlled, multicentre cohort study of patients with EP treated with SEC in daily practice conditions conducted between December 2015 and July 2020. Dermatologists from one Portuguese and six Spanish hospitals participated in this study. Inclusion criteria were (1) adults diagnosed of EP (involvement of >80% of body surface area) treated with SEC in a daily practice setting; (2) initial standard dose regimen of SEK; (3) follow‐up for at least 3 months. Effectiveness (Psoriasis Area and Severity Index, PASI) and quality of life (Dermatology Life Quality Index, DLQI) were evaluated through both. As observed and last observation carried forward (LOCF) analyses.Sixteen patients were included in the study. Baseline characteristics of the patients are summarized in Table 1. Five (31.2%) and 7 (43.7%) patients were naïve to conventional and biologic systemic therapy, respectively. Mean PASI, absolute and relative PASI, DLQI and Physician Global assessment

Journal

Journal of the European Academy of Dermatology and Venereology – Wiley

Published: Dec 1, 2023

There are no references for this article.